Orthogon Therapeutics
Meeting a critical need in translational drug discovery by bridging frontier research with formal drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | $5.2m Valuation: $40.0m | Early VC |
| Total Funding | 000k | ||
Related Content
Orthogon Therapeutics is a biopharmaceutical company that specializes in the development of antiviral medicines for challenging drug targets. The company's primary focus is on creating small molecule therapies, with a lead candidate being the first-ever oral treatment for BK polyomavirus, a significant viral complication for transplant recipients.
By leveraging advanced structure-based drug design and biophysics, Orthogon Therapeutics designs and develops its therapies. The company's business model is centered on research and development, with the goal of bringing new antiviral drugs to market. Its target market includes transplant patients and others who are susceptible to opportunistic viral infections. The company generates revenue through financing and partnerships to advance its drug candidates through the development and clinical trial process.
Keywords: antiviral, small molecules, BK polyomavirus, transplant patients, drug design, biophysics, anti-infective, preclinical, therapies, structure-based